Rafe Pomerance, Environmental Lobbyist Focused on Climate, Dies at 79
Rafe Pomerance died Thursday in Washington at age 79. He worked as a lobbyist for Friends of the Earth and helped bring attention to climate change in the late 1970s and 1980s.
washingtonpost.comRafe Pomerance died Thursday in a Washington hospital. He was 79. His stepson, Benjamin Cooley, said the cause was lung cancer. Pomerance read a 1979 Environmental Protection Agency report that stated coal emissions could warm the planet to a significant and damaging degree. He then worked to alert members of Congress and executive branch agencies to the findings.
In the 1970s and early 1980s, Pomerance served as a lobbyist for the environmental group Friends of the Earth. He was not a scientist or lawyer. Nathaniel Rich wrote in a 2018 New York Times Magazine article that Pomerance was the central figure in the emergence of climate change as a political issue during that period.
The 2018 article, later expanded into a book, described the decade from 1979 to 1989 as a period when both Republican and Democratic leaders pledged to address the issue. Rich stated that Pomerance preferred not to be the public messenger. Rich described Pomerance as voluble, energetic and obsessive in an interview with The New York Times.
Key Facts
Story Timeline
3 events- 1979
Pomerance read an EPA report on coal emissions and climate effects.
1 sourceThe New York Times - 2018
Nathaniel Rich profiled Pomerance in The New York Times Magazine article Losing Earth.
1 sourceThe New York Times - 2026-05-22
Rafe Pomerance died in a Washington hospital at age 79.
1 sourceThe New York Times
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.